Article

Orphan status given to two drugs

Jersey City, NJ-The FDA has granted orphan drug designation to two investigational therapeutics of Lux Biosciences, a privately held biotechnical company specializing in treatments for ophthalmic diseases.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
Related Content
FDA approves first biosimilar product for retinal diseases
November 1st 2021

Making the grade: FDA approves first biosimilar product for retinal diseases

Advancement in TED treatment is a bright spot
June 30th 2021

Advancement in TED treatment is a bright spot

Comparable conscious sedation methods address individual patient needs
April 14th 2021

Comparable conscious sedation methods address individual patient needs

Investigators uncover health care disparities among US patients
April 2nd 2021

Investigators uncover health care disparities among US patients

Investigators zoom in on future of dry eye treatment
March 2nd 2021

Investigators zoom in on future of dry eye treatment

Analyzing opioid prescription patterns of US retina specialists
November 16th 2020

Analyzing opioid prescription patterns of US retina specialists

© 2024 MJH Life Sciences

All rights reserved.